Every-other-day dosing for patients on the go
FEIBA Guidelines for Dosing
Patients with inhibitors present a difficult clinical challenge. Bypassing agents, such as FEIBA, play an important role in the management of inhibitors.1,15,16
Use this guide to help when determining the appropriate dose for your patients based on weight, dosing schedule and type of bleeding episode.
1. Select your patient’s body weight
- 22 lb (10 kg)
- 33 lb (15 kg)
- 44 lb (20 kg)
- 55 lb (25 kg)
- 66 lb (30 kg)
- 77 lb (35 kg)
- 88 lb (40 kg)
- 99 lb (45 kg)
- 110 lb (50 kg)
- 121 lb (55 kg)
- 132 lb (60 kg)
- 143 lb (65 kg)
- 154 lb (70 kg)
- 165 lb (75 kg)
- 176 lb (80 kg)
- 187 lb (85 kg)
- 198 lb (90 kg)
- 209 lb (95 kg)
- 220 lb (100 kg)
- 231 lb (105 kg)
- 242 lb (110 kg)
- 253 lb (115 kg)
- 264 lb (120 kg)
- 275 lb (125 kg)
- 286 lb (130 kg)
- 297 lb (135 kg)
- 308 lb (140 kg)
2. Select dosing schedule
3. Select type of bleeding episode
Dose range: 50 U/2.2 lb (50 U/kg) - 100 U/2.2 lb (100 U/kg)
Total FEIBA units range: to
Dose: 85 U/2.2 lb (85 U/kg)
Total FEIBA units:
Frequency of doses (hours): 6
Duration of therapy: At least 1 day or until bleeding is resolved
Healthcare professionals are ultimately responsible to determine the appropriate dose for each patient based on patient examination, characteristics, and medical judgment.
Dosage and duration of treatment depend on the location and extent of bleeding, and the patient’s clinical condition. Careful monitoring of replacement therapy is necessary in cases of major surgery of life-threatening bleeding episodes.1
Base the dose and frequency of FEIBA on the individual clinical response. Clinical response to treatment with FEIBA may vary by patient, and may not correlate with the patient’s inhibitor titer.1
Do not exceed a single dose of 100 units per kg body weight and a daily dose of 200 units per kg body weight.1
Selected Important Risk Information for FEIBA [Anti-Inhibitor Coagulant Complex]
WARNING: THROMBOEMBOLIC EVENTS
- Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA, particularly following the administration of high doses and/or in patients with thrombotic risk factors.
- Monitor patients receiving FEIBA for signs and symptoms of thromboembolic events.
Because FEIBA is made from human plasma it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
The most frequently reported adverse reactions observed in >5% of subjects in the prophylaxis trial were anemia, diarrhea, hemarthrosis, hepatitis B surface antibody positive, nausea, and vomiting.
The serious adverse reactions seen with FEIBA are hypersensitivity reactions and thromboembolic events, including stroke, pulmonary embolism and deep vein thrombosis.
Use of antifibrinolytics within approximately 6 to 12 hours after the administration of FEIBA is not recommended.